Aims Arrhythmogenic right ventricular cardiomyopathy (ARVC) patients develop ventricular
arrhythmias (VAs) responsive to anti-tachycardia pacing (ATP). However, VA episodes have …

Abstract Background and Aims Implantable cardioverter-defibrillators (ICDs) are critical for
preventing sudden cardiac death (SCD) in arrhythmogenic right ventricular cardiomyopathy …

Objective Arrhythmogenic right ventricular cardiomyopathy (ARVC) is associated with a risk
of sudden cardiac death. Optimal risk stratification is still under debate. The main purpose of …

Introduction Implantable cardioverter-defibrillators (ICDs) can prevent sudden cardiac death
due to ventricular arrhythmias in patients with arrhythmogenic right ventricular …

Background There is limited evidence guiding the selection between subcutaneous and
transvenous implantable cardioverter-defibrillators (ICDs) in patients with arrhythmogenic …

Implantable cardioverter-defibrillator (ICD) therapy remains a corner stone of sudden
cardiac death (SCD) prevention in patients with arrhythmogenic right ventricular …

Aims Treatment with implantable cardioverter-defibrillators (ICD) is a cornerstone for
prevention of sudden cardiac death in arrhythmogenic right ventricular cardiomyopathy …

Aims Arrhythmogenic right ventricular cardiomyopathy (ARVC) patients have an increased
risk of ventricular arrhythmias (VA). Four implantable cardioverter-defibrillator (ICD) …

Objectives: The primary objective of this study is risk stratification of patients with arrhythmic
right ventricular cardiomyopathy (ARVC). Background: There is a need to identify those who …

Aims The roles of implantable cardioverter-defibrillators (ICDs) and radiofrequency catheter
ablation (RCA) in patients with arrhythmogenic right ventricular cardiomyopathy (ARVC) and …